Welcome to our dedicated page for Aptorum Group SEC filings (Ticker: APM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptorum Group Limited's SEC filings document its foreign private issuer reporting, corporate governance and capital-structure disclosures. Form 6-K reports include annual general meeting proxy materials, shareholder voting results, board-election items, auditor ratification matters and disclosures tied to Class A Ordinary Shares and Class B Ordinary Shares.
The company's filings also cover material-event reports, material agreements, operating and financial results, registration-statement references on Form S-8 and Form F-3, and Nasdaq listing-compliance notices. These records frame APM's pharmaceutical development business alongside its governance, share structure, risk factors and public-company reporting obligations.
Aptorum Group Limited reports that its shareholders approved a proposed all-stock merger with DiamiR Biosciences Corp. at an extraordinary general meeting. Shareholders representing 2,848,680 Class A and Class B shares, or 97.15% of the voting power entitled to vote, were present by proxy, and all proposals passed with overwhelming support. DiamiR’s shareholders also approved the merger on the same date. The merger will make DiamiR a wholly owned subsidiary of Aptorum, but completion still depends on satisfying or waiving remaining customary closing conditions, and the companies currently expect the transaction to close before fiscal 2027.
Aptorum Group Limited is registering up to 2,060,000 Class A Ordinary Shares issuable upon the exercise of certain warrants for resale by the named Selling Securityholders.
The registration covers (i) up to 2,000,000 Investor Warrant Shares exercisable at $2.00 per share (October 2025 Warrants) and (ii) 60,000 Placement Agent Warrant Shares exercisable at $2.50 per share. The Company states it will not receive proceeds from Selling Securityholders’ resale transactions but will receive cash exercise proceeds when warrants are exercised for cash. The prospectus warns that large resales could pressure the market; the last reported sale price was $1.09 per share as of June 3, 2026.
Aptorum Group Limited filed a post-effective amendment to register up to 2,060,000 Class A Ordinary Shares issuable upon exercise of warrants (the “2025 Warrants”), including 2,000,000 Investor Warrants at an original exercise price of $2.00 and 60,000 Placement Agent Warrants at $2.50. The prospectus registers resale by the selling securityholders; the Company will not receive proceeds from resale but will receive cash exercise proceeds when warrants are exercised for cash. The filing discloses risks tied to the Company’s Hong Kong operations, PRC regulatory uncertainty including the CSRC Trial Measures and HFCAA/PCAOB inspection risks, and summarizes the pending DiamiR merger and related governance, consideration and conditionality.
Aptorum Group plans to issue 19,917,413 shares of Aptorum Delaware common stock to DiamiR Biosciences stockholders as consideration in a planned merger. Existing Aptorum holders would receive 9,536,034 common shares and 1,796,934 non‑voting Series A preferred shares upon a redomiciling to Delaware. After closing, DiamiR investors are expected to own about 70% of the combined company and current Aptorum shareholders about 30%. Aptorum will deregister from the Cayman Islands, domesticate in Delaware, consolidate its shares at a 2‑for‑1 to 10‑for‑1 ratio, adopt a 4,500,000‑share incentive plan, and rename the combined business Niki BioSolutions, Inc., with stock expected to trade on Nasdaq under the symbol “NIKI.”
Aptorum Group Limited files a Pre-Effective Amendment No. 3 to a Form S-4 registering securities in connection with a proposed merger with DiamiR Biosciences Corp. The filing describes a domestication from the Cayman Islands to Delaware, a Merger under a July 14, 2025 Merger Agreement, and related shareholder action items to be voted at a Special Meeting.
The proxy/prospectus discloses the proposed exchange mechanics (a Conversion Ratio formula), pro forma ownership (DiamiR ~70% and Aptorum ~30% immediately after closing), an example issuance of 9,536,034 Aptorum Delaware common shares and 1,796,934 Series A preferred shares to current Aptorum holders if issued on April 30, 2026, and an illustrative issuance of 19,917,413 Aptorum Delaware common shares to DiamiR stockholders. The filing describes contractual interim payments: a management services fee increased to $105,000 per month and an IP license upfront payment of $5,000 plus monthly $1,200.
Aptorum Group Limited files a Form S-4 pre-effective amendment registering 19,917,413 shares of Aptorum Delaware common stock for issuance to DiamiR Biosciences stockholders in a planned merger. Existing Aptorum holders would receive 9,536,034 common shares and 1,796,934 Series A preferred shares upon domestication to Delaware.
After the merger, DiamiR and current Aptorum shareholders are expected to own about 70% and 30% of the combined company, which plans to be renamed Niki BioSolutions, Inc. and trade on Nasdaq as “NIKI.” Proposals include a reverse stock split, Cayman-to-Delaware domestication, a new 2025 incentive plan, and board reconstitution.
CEO Ian Huen controls roughly 86.7% of voting power and has agreed to vote in favor of all proposals, effectively assuring approval. The filing also details Hong Kong/PRC regulatory and HFCAA-related audit risks, cash transfers to subsidiaries, and management and IP agreements with DiamiR extended to June 30, 2026.
Aptorum Group Limited (APM) files a Pre-Effective Amendment to a Form S-4 to register shares in connection with its proposed merger with DiamiR Biosciences Corp. Under the Merger Agreement, the surviving public company will domesticate to Delaware and be renamed Niki BioSolutions, Inc.
The transaction contemplates a post-closing ownership mix of approximately 70% for DiamiR stockholders and 30% for existing Aptorum shareholders. The proxy seeks shareholder approvals for a share consolidation, Domestication, issuance of shares exceeding 20% of outstanding common stock to DiamiR stockholders, a new equity incentive plan, director appointments and related matters. Major holder Jurchen Investment Corporation (controlled by CEO Ian Huen) holds voting power of ~86.71%, and has entered into a voting agreement in support of the proposals.
Aptorum Group Limited, a Cayman Islands-based biopharma company listed on the Nasdaq Capital Market, files its annual report describing a clinical‑stage business with no revenue from product sales and a heavy reliance on raising additional capital to fund operations.
The company highlights extensive risks around its preclinical and clinical drug pipeline, regulatory approvals, intellectual property protection, dependence on third parties, and operating exposure to Hong Kong and PRC regulatory regimes. Its auditor has expressed substantial doubt about Aptorum’s ability to continue as a going concern, and the company also warns about potential Nasdaq delisting, PCAOB inspection issues, and concentrated voting control through Class B shares.